Novartis injects €150m in Austrian biologics fill/finish facility
The €150m ($172m) investment has added extra capacity to Novartis’s biosimilar and proprietary biologics network.
Archives for September 17, 2015
Interchangeability key to US biosimilars market says expert
Interchangeability can create long-lasting price competition in the nascent US biosimilars market according to a Berkeley health policy expert.
Senate Committee to US FDA: Where are the biosimilar guidelines?
FDA’s Janet Woodcook has defended delays in producing biosimilar interchangeability and labelling guidances, saying the scientific framework must first be ‘bulletproof.’